|Jesper Boysen – CEO and Board Member
Jesper has extensive strategic, commercial and business development experience from previous senior management positions in the Med Tech industry. He has been EVP at Mediq BV, CEO at Mediq Danmark, CEO at SDC DanDisc A/S and Nordic general manager at Mølnlycke Health Care. Jesper is founder and CEO of Micocou Holding and holds an E-MBA, Graduate Diploma in Business Administration, Finance and Marketing Management.
|Hanne Leth Hillman – Chief Financial Officer
Hanne has broad based competences within finance, capital and investor market relations and corporate communication. She has 10+ years of experience from senior management positions in publicly listed life science companies and 10+ years of experience from positions in life science investment banking, corporate finance and equity research. Hanne holds an MBA, International Finance.
|Sten Naae Hornsleth – Director, Sales and Marketing
Sten joined Nanovi as Director of Sales and Marketing in January 2019. Photo and biography will follow shortly.
|Hsiao-Qing Chow – Director, Regulatory Affairs
Chow joined Nanovi in 2016 as Senior Regulatory Affairs Manager and was appointed Director of Regulatory Affairs in 2018 with responsibility for regulatory affairs, Quality Assurance, design control and risk management. Chow has +7 years of experience from positions in the medical device industry, including several years with Coloplast. Chow holds a Master of Science in Pharmacy.
|Michael Wrang Mortensen – Director, Development & Supply
Michael joined Nanovi in 2018. He has +10 years of experience from the Med Tech industry, including several years with Ferrosan Medical Devices A/S/ Ethicon Biosurgery Inc., Johnson & Johnson. He has held management and leadership positions in global R&D teams as well as in commercial development and operational projects in both small and international organizations. Michael holds a Master of Science in Engineering from the Danish Technical University and a PhD degree in Chemistry .
Board of Directors:
|Simon Hesse Hoffmann, Chairman
Simon joined the Board in May 2018 and became Chairman of the Board in December 2018. He is Director of JHO Holding ApS and has previously held financial positions in several publicly listed Danish companies, including a position as Head of Group Treasury in DFDS A/S. His experience spans financial management, governance and reporting as well as budgeting and corporate funding. Simon is member of the board in HolmeTex ApS, 2CureX A/S and WireOnAir A/S and is Chairman of the Board in the SMIL Foundation (SMILfonden) . Simon holds a Master of Science in Finance and International Business.
CEO and Board Member. Jesper was previously EVP at Mediq BV, CEO at Mediq Danmark, CEO at SDC DanDisc A/S and Nordic general manager at Mølnlycke Health Care. Jesper is founder and CEO of Micocou Holding and holds an E-MBA, Graduate Diploma in Business Administration (Finance) and (Marketing Management).
Ole is Investment Director in Vækstfonden’s Life Science team and represents Vækstfonden on the Board of Directors. Ole has extensive management, commercial and operational experience. He is the founder of Scandinavian Micro Biodevices, where he was CEO for 12 years, including after the company was acquired by Zoetis Inc. in 2016. Ole holds a Master of Science in Economy & Business Administration.
Flemming has several board positions including of 3Shape Group. President & CEO of 3Shape Group from its inception in 2001 to 2017. Held senior executive positions at Amersham/ Nycomed and Novo Nordisk. M.Sc in Economics and M.Sc in Management
MD, Professor. Gordon is an international authority on the treatment and research of cancer. He is the co-founding editor of ecancermedicalscience, an open-access cancer journal. He is Chair of Proton Partners International, Visiting professor at Kings College, London and Senior clinical advisor, Italian Laboratory for Molecular Oncology. Previously CEO of Cancer Research UK.
Thomas L. Andresen
Thomas is the founder of Nanovi. He is Master of Science, Ph.D and Professor at Danish Technological University (DTU), Healthtech, where he also leads the “Colloids and Biological Interfaces” group. Thomas has more than 20 years of research and development experience in the fields of organic chemistry, biophysics, advanced materials engineering, and cancer biology and is an author on more than 100 research or review articles and multiple patent applications. Thomas is Chief Scientific Officer and a co-founder at Torque Therapeutics Inc, a Boston, US based biopharmaceutical company, developing cell therapies for cancer.